Brustkrebs ist nicht gleich Brustkrebs
Senologen sehen Brustkrebs als individuelle Erkrankung - Umsetzung des Brustkrebs-Screeningprogramms ab April 2013

Pro Jahr erkranken in Österreich rund 5.000 Frauen an einem Mammakarzinom. Doch die moderne Medizin "zerteilt" den Oberbegriff "Brustkrebs" in immer mehr Untereinheiten, um besser und möglichst wenig belastend behandeln zu können.
mehr ......

hallo Uschi,
ich habe hier einen aktuellen Artikel gefunden (leider in englisch); falls jemand wirklich interessiert ist, übersetze ich das Wichtigste
liebe Grüsse
Heinz

Breast cancer drug offers women a lifeline
A NEW breast cancer treatment could offer a lifeline for women with the most aggressive form of the disease without side effects such as hair loss.
The drug, known as T-DM1, has been shown to increase the length of survival of some hard-to-treat patients by almost six months. Results of a major trial showed it extended the lives of patients with advanced HER2-positive breast cancer by 30.9 months compared with 25.1 months with standard therapy.
About 10,000 British women are diagnosed with HER2-positive breast cancer each year, representing about one in five of those affected. Paul Ellis, professor of cancer medicine at King's College, London, said this type of cancer was "very aggressive" and once it reached the advanced stage became "very difficult to treat".
"These results are truly outstanding and will positively alter the outlook and outcomes for patients," he said. "Drugs used at this stage of the disease often make women feel worse, but the beauty of this treatment is that it costs women fewer side effects such as hair loss and improves their quality of life."
Conclusions from the trial, involving 991 women, were presented yesterday at the European Society for Medical Oncology's annual meeting in Vienna.
T-DM1 combines the drug Herceptin with a powerful chemotherapy agent and is designed to destroy cancer cells by penetrating them. Because its action is so precise, a normally toxic form of chemotherapy can be used with few side effects. Manufacturer Roche hopes to obtain a licence to market the drug in the UK.
Prof Ellis said the trial results were remarkable in patients with advanced disease who had relapsed on existing treatment. He said 1,000 such women a year in the UK would benefit from it. Eventually it could also be used at an earlier stage.
The drug carries out a two-stage attack on cancerous cells, attaching to the tumour cell and blocking signals that allow the cancer to spread. It then breaches outer defences and releases chemotherapy to destroy the cancer from within, sparing healthy tissue unnecessary damage. The result is that the cancer's return is also delayed while side effects of chemotherapy such as diarrhoea and hair loss are reduced.
Baroness Morgan, the chief executive of the Breast Cancer Campaign, said: "This 'smart' drug could be a precious lifeline for women with HER2-positive advanced breast cancer who currently have limited treatment options.
"We hope it will be made available to women as early as possible."
Carolyn Rogers, senior clinical nurse specialist at the charity Breast Cancer Care, said: "The findings are encouraging as currently there are limited treatment options for people living with this type of breast cancer."
Dr Caitlin Palframan, of Breakthrough Breast Cancer, said: "While these results are good, this treatment still has some way to go before it could be made generally available in this country."